Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2119

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2119
---
 us with competitive advantages and may make us a partner of choice to research universities
and medical centers, we face substantial competition from pharmaceutical companies as well as established and venture-backed biotechnology
companies worldwide. For example, other companies such as BridgeBio similarly target research universities and medical centers to identify
and develop therapeutic candidates that may or may not overlap with the inventions or technologies that we may seek to develop. As a
result, we may face competition from other companies that are seeking to gain access to the types of institutions that we may seek to
partner with. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As
a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.

Competition
for Existing Product Candidates

We
face competition with respect to our current product candidates and will face competition with respect to future product candidates,
from pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions,
among others.

If
our current product candidates or our future product candidates do not offer sustainable advantages over competing products, we may otherwise
not be able to successfully compete against current and future competitors.

Our
competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual
property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that
are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors
may also be more successful than us in manufacturing and marketing their products.

In
addition, we may likely need to develop certain of our product candidates in collaboration with diagnostic companies, and we will face
competition from other companies in establishing these collaborations. Our competitors will also compete with us in recruiting and retaining
qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials,
as well as in acquiring technologies complementary to, or necessary for, our programs.

Furthermore,
we also face competition more broadly across the market for cost-effective and reimbursable treatments. Some of these competitive drugs
are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may
also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they